Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS118 in advanced malignancies
NCT03440437Phase 2Terminated
- Sponsor
- invoX Pharma
- Start
- Apr 2018
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of FS118 in solid tumor (advanced stage), squamous cell carcinoma of the head and neck (HNSCC), sponsored by invoX Pharma. Started Apr 2018; status: terminated.
02
Drugs
FS118
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03440437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03440437.